Point72 DIFC Ltd Takes $1.42 Million Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Point72 DIFC Ltd acquired a new stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 55,757 shares of the company's stock, valued at approximately $1,420,000. Point72 DIFC Ltd owned approximately 0.11% of Bicara Therapeutics at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Cinctive Capital Management LP bought a new position in shares of Bicara Therapeutics during the 3rd quarter valued at about $229,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Bicara Therapeutics during the 3rd quarter valued at about $462,000. The Manufacturers Life Insurance Company bought a new position in shares of Bicara Therapeutics during the 3rd quarter valued at about $582,000. Walleye Capital LLC bought a new position in shares of Bicara Therapeutics during the 3rd quarter valued at about $809,000. Finally, Maven Securities LTD bought a new position in shares of Bicara Therapeutics during the 3rd quarter valued at about $1,274,000.

Insider Activity at Bicara Therapeutics

In other Bicara Therapeutics news, Director Ra Capital Management, L.P. acquired 1,833,000 shares of the business's stock in a transaction that occurred on Monday, September 16th. The shares were purchased at an average price of $18.00 per share, with a total value of $32,994,000.00. Following the completion of the transaction, the director now owns 4,303,418 shares in the company, valued at $77,461,524. The trade was a 74.20 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder James E. Flynn acquired 70,000 shares of the business's stock in a transaction that occurred on Tuesday, September 17th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $1,260,000.00. Following the transaction, the insider now owns 897,587 shares of the company's stock, valued at approximately $16,156,566. This represents a 8.46 % increase in their position. The disclosure for this purchase can be found here.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on BCAX shares. Morgan Stanley started coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set an "overweight" rating and a $35.00 price objective for the company. Stifel Nicolaus started coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They issued a "buy" rating and a $47.00 target price for the company. Cantor Fitzgerald started coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They issued an "overweight" rating for the company. Rodman & Renshaw started coverage on shares of Bicara Therapeutics in a report on Tuesday, November 5th. They issued a "buy" rating and a $48.00 target price for the company. Finally, TD Cowen assumed coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They issued a "buy" rating for the company. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $43.33.

Bicara Therapeutics Stock Performance

Shares of BCAX stock traded down $0.41 during trading on Thursday, hitting $19.54. 220,374 shares of the company were exchanged, compared to its average volume of 353,903. The business's 50-day moving average is $21.82. Bicara Therapeutics Inc. has a twelve month low of $17.41 and a twelve month high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($0.46) by ($1.14). Sell-side analysts predict that Bicara Therapeutics Inc. will post -2.89 EPS for the current year.

Bicara Therapeutics Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.